Targeting a specific protein to fight drug-resistant breast cancer cells
Targeting eIF4A1 in drug-resistant breast cancer stem-like cells
This study is looking at how a protein called eIF4A1 affects stubborn breast cancer cells that don’t respond to chemotherapy, with the goal of finding new ways to help patients with triple-negative breast cancer get better treatment options.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of Toledo Health Sci Campus NIH-funded |
| Lab location | 1 site (Toledo, United States) |
| Project ID | NIH-10890065 on NIH RePORTER |
What this research studies
This research investigates how the protein eIF4A1 influences the behavior of breast cancer stem-like cells that are resistant to chemotherapy. By understanding the mechanisms that allow these cells to survive and proliferate, the research aims to develop new strategies to overcome drug resistance in triple-negative breast cancer (TNBC). The approach involves studying the interactions between eIF4A1, pluripotency factors, and drug transporters, which could lead to innovative treatment options for patients. If successful, this research could provide insights into more effective therapies for those with aggressive breast cancer.
Who could benefit from this research
Good fit: Ideal candidates for this research are patients with triple-negative breast cancer who have experienced resistance to standard chemotherapy treatments.
Not a fit: Patients with non-breast cancers or those whose breast cancer is not triple-negative may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to new treatments that effectively target and eliminate drug-resistant breast cancer cells, improving survival rates for patients.
How similar studies have performed: Previous research has shown promise in targeting similar pathways in cancer treatment, suggesting that this approach could yield significant advancements.
Where this research is happening
Toledo, United States
- University of Toledo Health Sci Campus — Toledo, United States (Active)
Researchers
- Principal investigator: Raman, Dayanidhi — University of Toledo Health Sci Campus
- Study coordinator: Raman, Dayanidhi
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.